Registry of Patients With Plasma Cell Disorders

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorSiriraj Hospital

About this trial

The goal of this observational study is to register patients with plasma cell disorders. The main questions it aims to answer are:

* The incidence of plasma cell disorders both before and after malignancy * Time to progression of monoclonal gammopathy of undetermined significant (MGUS) or smoldering multiple myeloma (SMM) to light chain amyloidosis or multiple myeloma (MM) * Progression free survival (PFS) * overall survival * factors influencing overall survival, progression-free survival, and time to progression * Symptoms and signs of the disease during the diagnosis and relapse phases, including the causes of mortality in plasma cell disorder patients. * genetic characteristics of plasma cell disorder * cost-effectiveness of treatment in Thailand Participants will be collected the data of baseline diagnosis, treatment, treatment results of all admission and follow-up visits from hospital medical record.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Both existing and newly diagnosed patients with plasma cell disorders, including monoclonal gammopathy of undetermined significance, smoldering multiple myeloma, POEMS, light chain amyloidosis, solitary plasmacytoma, and multiple myeloma, according to the diagnostic criteria of the International Myeloma Working Group 2014

Aged 18 years and above

Disqualifiers

insufficient data needed for analysis

Trial population

plasma cell disorder patients

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

register the plasma cell disorder patients

register the plasma cell disorder patients

Time frame
10 years

Secondary outcomes

1

incidence of plasma cell disorders

incidence of plasma cell disorders both before and after malignancy

Time frame
10 years
2

Time to progression

\- Time to progression of monoclonal gammopathy of undetermined significant (MGUS) or smoldering multiple myeloma (SMM) to light chain amyloidosis or multiple myeloma (MM)

Time frame
10 years
3

Progression free survival

Progression free survival

Time frame
10 years
4

overall survival

overall survival

Time frame
10 years

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: